SILO PHARMA, INC. Accrued Investment Income Receivable
SILO PHARMA, INC. (SILO) had Accrued Investment Income Receivable of $8.39 thousand as of 2023-06-30, per its 10-Q filed 2023-08-11.
Discontinued › Balance Sheet › Assets
us-gaap:AccruedInvestmentIncomeReceivable · last filed 2023-08-11
- 2023-06-30: Accrued Investment Income Receivable $8.39K.
- 2022-12-31: Accrued Investment Income Receivable $6.01K; Accrued Investment Income Receivable as first filed $7.19K.
- 2021-12-31: Accrued Investment Income Receivable $6.16K.
| Period end | Accrued Investment Income Receivable | Accrued Investment Income Receivable as first filed |
|---|---|---|
| 2023-06-30 | $8.39K 10-Q · filed 2023-08-11 | |
| 2022-12-31 | $6.01K 10-Q · filed 2023-08-11 | $7.19K 10-Q · filed 2023-05-12 |
| 2021-12-31 | $6.16K 10-Q · filed 2023-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |